Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Impact of C-Reactive Protein and Coronary Artery Calcium on Benefit Observed With Atorvastatin.

Blaha MJ, Nasir K, Budoff MJ, Dardari ZA, Blumenthal RS, Pollack S, Reichek N, Guerci AD.

J Am Coll Cardiol. 2018 May 29;71(21):2487-2488. doi: 10.1016/j.jacc.2018.03.478. No abstract available.

2.

A distal intergenic region controls pancreatic endocrine differentiation by acting as a transcriptional enhancer and as a polycomb response element.

van Arensbergen J, Dussaud S, Pardanaud-Glavieux C, García-Hurtado J, Sauty C, Guerci A, Ferrer J, Ravassard P.

PLoS One. 2017 Feb 22;12(2):e0171508. doi: 10.1371/journal.pone.0171508. eCollection 2017.

3.

Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.

Waheed S, Pollack S, Roth M, Reichek N, Guerci A, Cao JJ.

Atherosclerosis. 2016 Dec;255:193-199. doi: 10.1016/j.atherosclerosis.2016.09.060. Epub 2016 Sep 17.

PMID:
27693004
4.

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S; GFM, FISM AND D-MDS.

Haematologica. 2016 Jul;101(7):e280-3. doi: 10.3324/haematol.2016.142695. Epub 2016 Apr 7. No abstract available.

5.

Polymorphic Variants in Oxidative Stress Genes and Acute Toxicity in Breast Cancer Patients Receiving Radiotherapy.

Córdoba EE, Abba MC, Lacunza E, Fernánde E, Güerci AM.

Cancer Res Treat. 2016 Jul;48(3):948-54. doi: 10.4143/crt.2015.360. Epub 2016 Jan 14.

6.

Coronary artery calcification score as tool for risk assessment among families with premature coronary artery disease.

Mulders TA, Taraboanta C, Franken LC, van Heel E, Klass G, Forster BB, Arad Y, Boekholdt SM, Groenink M, Fröhlich J, Guerci AD, Stroes ES, Pinto-Sietsma SJ.

Atherosclerosis. 2016 Feb;245:155-60. doi: 10.1016/j.atherosclerosis.2015.12.008. Epub 2015 Dec 11.

PMID:
26724526
7.

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group.

Cancer. 2015 Jul 15;121(14):2393-9. doi: 10.1002/cncr.29389. Epub 2015 Apr 6.

8.

High dose and long-term statin therapy accelerate coronary artery calcification.

Henein M, Granåsen G, Wiklund U, Schmermund A, Guerci A, Erbel R, Raggi P.

Int J Cardiol. 2015 Apr 1;184:581-6. doi: 10.1016/j.ijcard.2015.02.072. Epub 2015 Feb 24.

PMID:
25769003
9.

Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).

Bourgne C, Janel A, Berger J, Rapatel C, Tournilhac O, Hermet E, Guerci A, Lioret F, Briançon A, Bamdad M, Boiret-Dupré N, Berger MG.

Leuk Res. 2015 Mar;39(3):329-34. doi: 10.1016/j.leukres.2014.11.014. Epub 2014 Dec 13.

PMID:
25612940
10.

Nuclear actin and myocardin-related transcription factors control disuse muscle atrophy through regulation of Srf activity.

Collard L, Herledan G, Pincini A, Guerci A, Randrianarison-Huetz V, Sotiropoulos A.

J Cell Sci. 2014 Dec 15;127(Pt 24):5157-63. doi: 10.1242/jcs.155911. Epub 2014 Oct 24.

11.

Abdominal aortic calcium, coronary artery calcium, and cardiovascular morbidity and mortality in the Multi-Ethnic Study of Atherosclerosis.

Criqui MH, Denenberg JO, McClelland RL, Allison MA, Ix JH, Guerci A, Cohoon KP, Srikanthan P, Watson KE, Wong ND.

Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1574-9. doi: 10.1161/ATVBAHA.114.303268. Epub 2014 May 8. Erratum in: Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):e1.

12.

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.

Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS).

Am J Hematol. 2014 Apr;89(4):410-6. doi: 10.1002/ajh.23654. Epub 2014 Feb 6.

13.

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S.

Blood. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442. No abstract available.

14.

The natural history of coronary calcification: a meta-analysis from St Francis and EBEAT trials.

Henein MY, Koulaouzidis G, Granåsen G, Wiklund U, Guerci A, Schmermund A.

Int J Cardiol. 2013 Oct 9;168(4):3944-8. doi: 10.1016/j.ijcard.2013.06.057. Epub 2013 Jul 17.

PMID:
23870639
15.

Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis).

Budoff MJ, Young R, Lopez VA, Kronmal RA, Nasir K, Blumenthal RS, Detrano RC, Bild DE, Guerci AD, Liu K, Shea S, Szklo M, Post W, Lima J, Bertoni A, Wong ND.

J Am Coll Cardiol. 2013 Mar 26;61(12):1231-9.

16.

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.

Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Béné MC, Rose C, Dreyfus F, Fenaux P.

Ann Hematol. 2013 May;92(5):621-31. doi: 10.1007/s00277-013-1686-4. Epub 2013 Jan 29. Erratum in: Ann Hematol. 2013 May;92(5):633. Lambert, Christine [corrected to Lamberto, C].

PMID:
23358617
17.

Measurement of imatinib uptake by flow cytometry.

Bourgne C, Bamdad M, Janel A, Libert F, Gagnieu MC, Rapatel C, Pigeon P, Pereira S, Hermet E, Guerci A, Pereira B, Makhoul PC, Ansah AJ, Cahn JY, Guyotat D, Trouillier S, Berger J, Boiret-Dupré N, Berger MG.

Cytometry A. 2012 Nov;81(11):996-1004. doi: 10.1002/cyto.a.22118. Epub 2012 Aug 28.

18.

[Srf: a key factor controlling skeletal muscle hypertrophy by enhancing the recruitment of muscle stem cells].

Guerci A, Lahoute C, Hébrard S, Collard L, Daegelen D, Sotiropoulos A.

Med Sci (Paris). 2012 May;28(5):468-70. doi: 10.1051/medsci/2012285008. Epub 2012 May 30. French. No abstract available.

19.

Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: the Multiethnic Study of Atherosclerosis study.

Wong ND, Nelson JC, Granston T, Bertoni AG, Blumenthal RS, Carr JJ, Guerci A, Jacobs DR Jr, Kronmal R, Liu K, Saad M, Selvin E, Tracy R, Detrano R.

JACC Cardiovasc Imaging. 2012 Apr;5(4):358-66. doi: 10.1016/j.jcmg.2011.12.015.

20.

Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.

Bally C, Fadlallah J, Leverger G, Bertrand Y, Robert A, Baruchel A, Guerci A, Recher C, Raffoux E, Thomas X, Leblanc T, Idres N, Cassinat B, Vey N, Chomienne C, Dombret H, Sanz M, Fenaux P, Adès L.

J Clin Oncol. 2012 May 10;30(14):1641-6. doi: 10.1200/JCO.2011.38.4560. Epub 2012 Apr 2.

PMID:
22473162
21.

Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.

Mulders TA, Sivapalaratnam S, Stroes ES, Kastelein JJ, Guerci AD, Pinto-Sietsma SJ.

JACC Cardiovasc Imaging. 2012 Mar;5(3):252-60. doi: 10.1016/j.jcmg.2011.11.014.

22.

Srf-dependent paracrine signals produced by myofibers control satellite cell-mediated skeletal muscle hypertrophy.

Guerci A, Lahoute C, Hébrard S, Collard L, Graindorge D, Favier M, Cagnard N, Batonnet-Pichon S, Précigout G, Garcia L, Tuil D, Daegelen D, Sotiropoulos A.

Cell Metab. 2012 Jan 4;15(1):25-37. doi: 10.1016/j.cmet.2011.12.001.

23.

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.

Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Natarajan-Amé S, Tertian G, Slama B, Fenaux P, Dreyfus F.

Leuk Res. 2011 Nov;35(11):1530-3. doi: 10.1016/j.leukres.2011.07.007. Epub 2011 Jul 30.

PMID:
21803419
24.

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L.

Leuk Res. 2011 Nov;35(11):1444-8. doi: 10.1016/j.leukres.2011.05.034. Epub 2011 Jun 28.

PMID:
21715006
25.

Construction and validation of a dose-response curve using the comet assay to determine human radiosensitivity to ionizing radiation.

Güerci A, Zúñiga L, Marcos R.

J Toxicol Environ Health A. 2011;74(15-16):1087-93. doi: 10.1080/15287394.2011.582318.

PMID:
21707432
26.

Cytotoxic and genotoxic effects of defence secretion of Ulomoides dermestoides on A549 cells.

Crespo R, Villaverde ML, Girotti JR, Güerci A, Juárez MP, de Bravo MG.

J Ethnopharmacol. 2011 Jun 14;136(1):204-9. doi: 10.1016/j.jep.2011.04.056. Epub 2011 Apr 29.

PMID:
21549820
27.

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.

Braun T, de Botton S, Taksin AL, Park S, Beyne-Rauzy O, Coiteux V, Sapena R, Lazareth A, Leroux G, Guenda K, Cassinat B, Fontenay M, Vey N, Guerci A, Dreyfus F, Bordessoule D, Stamatoullas A, Castaigne S, Terré C, Eclache V, Fenaux P, Adès L.

Leuk Res. 2011 Jul;35(7):863-7. doi: 10.1016/j.leukres.2011.02.008. Epub 2011 Mar 10.

PMID:
21396711
28.

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, Pautas C, Berthou C, Guyotat D, Cony-Makhoul P, Gardembas M, Michallet M, Hayette S, Cayuela JM, Weiss IR, Réa D, Castaigne S, Mahon FX, Guilhot F, Rousselot P.

Leuk Res. 2011 Jun;35(6):777-82. doi: 10.1016/j.leukres.2010.11.004. Epub 2010 Dec 10.

PMID:
21145590
29.

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P; Intergroupe Français des Leucémies Myéloïdes Chroniques.

Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19.

PMID:
20965785
30.

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD.

Am J Gastroenterol. 2011 Jan;106(1):71-7. doi: 10.1038/ajg.2010.299. Epub 2010 Sep 14.

PMID:
20842109
31.

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.

Nicolini FE, Hayette S, Legros L, Rousselot P, Maloisel F, Tulliez M, Guerci A, Charbonnier A, Prébet T, Rigal-Huguet F, Chabane K, Magaud JP, Paillet C, Pivot C, Michallet M.

Leuk Res. 2011 Jan;35(1):80-6. doi: 10.1016/j.leukres.2010.04.010. Epub 2010 Jun 3.

PMID:
20605207
32.

Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.

Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F.

Leuk Res. 2010 Nov;34(11):1430-6. doi: 10.1016/j.leukres.2010.05.030. Epub 2010 Jun 26.

PMID:
20580086
33.

Coronary artery calcium score and risk classification for coronary heart disease prediction.

Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, Greenland P.

JAMA. 2010 Apr 28;303(16):1610-6. doi: 10.1001/jama.2010.461.

34.

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P; GFM (Groupe Francophone des Myélodysplasies).

Leuk Res. 2010 Jul;34(7):864-70. doi: 10.1016/j.leukres.2009.12.004. Epub 2010 Feb 2.

PMID:
20129667
35.

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.

Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, Fenaux P; European APL Group.

Blood. 2010 Mar 4;115(9):1690-6. doi: 10.1182/blood-2009-07-233387. Epub 2009 Dec 17.

36.

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.

Kelaidi C, Stamatoullas A, Beyne-Rauzy O, Raffoux E, Quesnel B, Guerci A, Dreyfus F, Brechignac S, Berthou C, Prebet T, Hicheri Y, Hacini M, Delaunay J, Gourin MP, Camo JM, Zerazhi H, Taksin AL, Legros L, Choufi B, Fenaux P; Groupe Francophone des Myélodysplasies.

Haematologica. 2010 Jun;95(6):892-9. doi: 10.3324/haematol.2009.014357. Epub 2009 Dec 16.

37.

Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.

Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L.

J Clin Oncol. 2009 Jun 1;27(16):2668-76. doi: 10.1200/JCO.2008.18.4119. Epub 2009 May 4.

PMID:
19414681
38.

Evaluation of radioadaptive response induced in CHO-K1 cells in a non-traditional model.

Grillo CA, Dulout FN, Guerci AM.

Int J Radiat Biol. 2009 Feb;85(2):159-66. doi: 10.1080/09553000902740143.

PMID:
19280469
39.

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.

Itzykson R, Ayari S, Vassilief D, Berger E, Slama B, Vey N, Suarez F, Beyne-Rauzy O, Guerci A, Cheze S, Thomas X, Stamatoullas A, Gardembas M, Bauduer F, Kolb A, Chaury MC, Legros L, Damaj G, Chermat F, Dreyfus F, Fenaux P, Ades L; Groupe Francophone des Myelodysplasies (GFM).

Leukemia. 2009 Apr;23(4):673-8. doi: 10.1038/leu.2008.362. Epub 2009 Jan 8.

PMID:
19151787
40.

Coronary calcium coverage score: determination, correlates, and predictive accuracy in the Multi-Ethnic Study of Atherosclerosis.

Brown ER, Kronmal RA, Bluemke DA, Guerci AD, Carr JJ, Goldin J, Detrano R.

Radiology. 2008 Jun;247(3):669-75. doi: 10.1148/radiol.2473071469. Epub 2008 Apr 15.

41.

Coronary calcium as a predictor of coronary events in four racial or ethnic groups.

Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA.

N Engl J Med. 2008 Mar 27;358(13):1336-45. doi: 10.1056/NEJMoa072100.

42.

Detection of excision repaired DNA damage in the comet assay by using Ara-C and hydroxyurea in three different cell types.

Güerci A, Liviac D, Marcos R.

Cell Biol Toxicol. 2009 Feb;25(1):73-80. Epub 2007 Nov 20.

PMID:
18027091
43.

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.

Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P.

Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1.

44.

Assessment of genotoxic damage in lymphocytes of hospital workers exposed to ionizing radiation in Argentina.

Güerci AM, Grillo CA, Dulout FN, Seoane AI.

Arch Environ Occup Health. 2006 Jul-Aug;61(4):163-9.

PMID:
17867570
45.

[Acquired alpha-thalassemia as early sign for myelodysplastic syndrome (refractory anaemia) with secondary haemochromatosis].

Perrin J, Perrot A, Chenot V, Lesesve JF, Guerci A, Marchand-Arvier M, Vigneron C, Lecompte T.

Ann Biol Clin (Paris). 2007 Jul-Aug;65(4):405-9. French.

46.

Highly restricted diversity of TCR delta chains of the amphibian Mexican axolotl (Ambystoma mexicanum) in peripheral tissues.

André S, Kerfourn F, Affaticati P, Guerci A, Ravassard P, Fellah JS.

Eur J Immunol. 2007 Jun;37(6):1621-33.

47.

The prognostic accuracy of coronary calcification.

Guerci AD.

J Am Coll Cardiol. 2007 May 8;49(18):1871-3. Epub 2007 Apr 20. No abstract available.

48.

Genetic instability induced by low doses of x-rays in hamster cells.

Seoane A, Güerci A, Dulout F.

Int J Radiat Biol. 2007 Feb;83(2):81-7.

PMID:
17357429
49.

Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group.

J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20.

PMID:
17116939
50.

Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology.

Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, Guerci AD, Lima JA, Rader DJ, Rubin GD, Shaw LJ, Wiegers SE; American Heart Association Committee on Cardiovascular Imaging and Intervention; American Heart Association Council on Cardiovascular Radiology and Intervention; American Heart Association Committee on Cardiac Imaging, Council on Clinical Cardiology.

Circulation. 2006 Oct 17;114(16):1761-91. Epub 2006 Oct 2. Review. No abstract available.

Supplemental Content

Loading ...
Support Center